-335 patients were randomized, 230 completed the study. Mean age 61, 70% male. Ethnicity data not provided, home 148/84 mm Hg, office 157/90 mm Hg, K 4.1 mEq/L, Cr 1.0 mg/dL, 24hr urine Na 137 mEq.
Baseline ACE/ARB, CCB, thiazide agent/dose were not specified.
-Figure: All agents resulted in statistically significant reductions in systolic pressure compared to placebo; spironolactone resulted in larger reductions than any other agent (p<0.05).
-Upon trial completion, K was 4.4 mEq/L in the spironolactone arm (unchanged with other agents), Cr 1.1 mg/dL in all groups.
-Discontinuation rates related to gynecomastia/sexual dysfunction, renal impairment, or hyperkalemia were no higher in the spironolactone group.